Metformin as a chemotherapeutic agent

Phase 1

Conditions: Endometrial carcinoma.
Malignant neoplasm of endometrium
C54.1

Registration Number: IRCT20220409054463N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 40

Inclusion Criteria

All women with endometrial carcinoma pathology, regardless of age and histological stage, who have referred to Mahdieh / Imam Hossein (AS) Medical Center between 1401-1402 and are on the list of staging surgery of this center.

Exclusion Criteria

Pregnancy
Diabetes or the use of metformin or other blood sugar control drugs
Liver or kidney dysfunction
Simultaneous cancers over the last 5 years
Use of chemotherapy drugs or hormone therapy during the last 3 months
Any allergy to Biguanides or contraindications to the use of this class of drugs

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in the expression of ki-67 gene in tissue samples of endometrial cancer after using metformin. Timepoint: Before treatment and on the day of surgery. Method of measurement: Ki-67 tissue staining (IHC).;Changes in p-53 gene expression in endometrial cancer tissue samples after metformin use. Timepoint: Before treatment and on the day of surgery. Method of measurement: P-53 tissue staining (IHC).;Determining the effect of metformin on tumor size reduction. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measurement of mass during diagnosis by ultrasound and by the surgeon.;Determining the effect of metformin use in reducing body mass index. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measuring Body Mass Index (weight over height^2).

Secondary Outcome Measures

Name	Time	Method
Changes in p-53 gene expression in endometrial cancer tissue samples after metformin use. Timepoint: Before treatment and on the day of surgery. Method of measurement: P-53 tissue staining (IHC).;Determining the effect of metformin on tumor size reduction. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measurement of mass during diagnosis by ultrasound and by the surgeon.;Determining the effect of metformin use in reducing body mass index. Timepoint: Before treatment and on the day of surgery. Method of measurement: Measuring Body Mass Index (weight over height^2).